SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.75 CNY | +7.01% |
|
+4.06% | -23.57% |
| Sales 2024 * | 4.81B 664M 907M | Sales 2025 * | 5.91B 816M 1.12B | Capitalization | 23.18B 3.2B 4.37B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.34B 185M 253M | Net income 2025 * | 1.75B 242M 330M | EV / Sales 2024 * | 4.83 x |
| Net Debt 2024 * | 57.28M 7.91M 10.81M | Net cash position 2025 * | 373M 51.47M 70.37M | EV / Sales 2025 * | 3.86 x |
| P/E ratio 2024 * |
16.8
x | P/E ratio 2025 * |
12.8
x | Employees | 2,018 |
| Yield 2024 * |
2.06% | Yield 2025 * |
2.49% | Free-Float | 51.45% |
More Fundamentals
* Assessed data
More news
More recommendations
| 1 day | +7.01% | ||
| 1 week | +4.06% | ||
| Current month | -5.21% | ||
| 1 month | -4.29% | ||
| 3 months | -9.74% | ||
| 6 months | -28.89% | ||
| Current year | -23.57% |
1 week
19.14
20.82
1 month
19.1422.67
Current year
18.4427.35
1 year
18.4434.18
3 years
18.44138.69
5 years
18.44156.06
10 years
1.82156.06
| Managers | Title | Age | Since |
|---|---|---|---|
Hui Zhou
DFI | Director of Finance/CFO | 52 | 21-12-29 |
Xiang Miao
PSD | President | 51 | 08-12-31 |
Wei Min Du
CHM | Chairman | 61 | 08-09-23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jiao Yu Li
BRD | Director/Board Member | 66 | 21-12-28 |
Wei Min Du
CHM | Chairman | 61 | 08-09-23 |
Jian Kai Liu
BRD | Director/Board Member | 54 | 08-09-23 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.60% | 2 M€ | -16.59% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 20.75 | +7.01% | 18,007,490 |
| 24-04-25 | 19.39 | -0.62% | 10,420,340 |
| 24-04-24 | 19.51 | -1.86% | 9,911,123 |
| 24-04-23 | 19.88 | -1.14% | 9,383,245 |
| 24-04-22 | 20.11 | +0.85% | 8,987,833 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
Shenzhen Kangtai Biological Products Co. specialises in the research, development and marketing of human vaccines. Products include vaccines against hepatitis B, haemophilus influenzae type B, measles and rubella.
Sector
Pharmaceuticals
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
20.75
CNY
Average target price
37.75
CNY
Spread / Average Target
+81.93%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.57% | 3.2B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- 300601 Stock
